Global Chemotherapy Induced Anemia Drugs and Companies Pipeline Review H2 2016

Chemotherapy Induced Anemia Market Research Report 2021

PUNE, INDIA, September 19, 2016 /EINPresswire.com/ -- The report provides comprehensive information on the therapeutics under development for Chemotherapy Induced Anemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chemotherapy Induced Anemia and features dormant and discontinued projects.

Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Complete Report @ https://www.wiseguyreports.com/reports/643479-chemotherapy-induced-anemia-pipeline-review-h2-2016



Scope

- The report provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Anemia

- The report reviews pipeline therapeutics for Chemotherapy Induced Anemia by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Chemotherapy Induced Anemia therapeutics and enlists all their major and minor projects

- The report assesses Chemotherapy Induced Anemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Chemotherapy Induced Anemia



Get Sample Report @ https://www.wiseguyreports.com/sample-request/643479-chemotherapy-induced-anemia-pipeline-review-h2-2016



Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Chemotherapy Induced Anemia

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Chemotherapy Induced Anemia pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Have any query @ https://www.wiseguyreports.com/enquiry/643479-chemotherapy-induced-anemia-pipeline-review-h2-2016



Table of Content

Chemotherapy Induced Anemia Overview 8

Therapeutics Development 9

Pipeline Products for Chemotherapy Induced Anemia - Overview 9

Chemotherapy Induced Anemia - Therapeutics under Development by Companies 10

Chemotherapy Induced Anemia - Pipeline Products Glance 12

Late Stage Products 12

Clinical Stage Products 13

Early Stage Products 14

Chemotherapy Induced Anemia - Products under Development by Companies 15

Chemotherapy Induced Anemia - Companies Involved in Therapeutics Development 16

3SBio Inc. 16

BIOCAD 17

Chong Kun Dang Pharmaceutical Corp. 18

Dr. Reddy's Laboratories Limited 19

Galenica Ltd. 20

Panacea Biotec Limited 21

Pfizer Inc. 22

PharmaEssentia Corporation 23

PhytoHealth Corporation 24

Pieris Pharmaceuticals Inc 25

Sandoz International GmbH 26

SBI Pharmaceuticals Co., Ltd. 27

Therapure Biopharma Inc. 28

Tolero Pharmaceuticals, Inc. 29

Chemotherapy Induced Anemia - Therapeutics Assessment 30

Assessment by Monotherapy Products 30

Assessment by Combination Products 31

Assessment by Target 32

Assessment by Mechanism of Action 34

Assessment by Route of Administration 36

Assessment by Molecule Type 38

Drug Profiles 40

(aminolevulinic acid hydrochloride + sodium ferrous citrate) - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

darbepoetin alfa - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

darbepoetin alfa - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

darbepoetin alfa - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

darbepoetin alfa - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

darbepoetin alfa - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

epoetin alfa - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

epoetin zeta - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

ferric carboxymaltose - Drug Profile 52



Buy now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=643479

Continued…

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here